Evicenter
P&T meetings

Emiltatug ledadotin (Emi-Le)

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
Last updated
125 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Nonclinical pharmacokinetics: cynomolgus monkeys

“The DAR 6 ADC (XMT-1660) and the DAR 2 ADC were evaluated at equal payload dose in a repeat-dose study in cynomolgus monkeys. Both ADCs exhibited comparable pharmacokinetics profiles, with comparable clearance rates and high stability in circulation, as indicated by the extremely low quantities of free payload (Fig. 3D).” (opens the source at this quote in a new tab)

Nonclinical biodistribution of released payload: rats

“These data demonstrate the comparable distribution of released drug between XMT-1660 and nonbinding control ADC, which suggests, based on this limited study, that the B7-H4-directed antibody component of XMT-1660 did not impact biodistribution. Moreover, no accumulation of the released drug was observed.” (opens the source at this quote in a new tab)

Human pharmacokinetics: exposure, half-life, clearance, and immunogenicity

No evidence found.